The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | The value of treating patients who are MRD negative
In this video, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some insights into the value of treating patients who are measurable residual disease (MRD) negative and the benefit of using MRD in multiple myeloma. Dr Costa also briefly discusses the promising results from the Cassiopeia trial (NCT02541383), including the complete response (CR) and progression-free survival (PFS) observed in patients. To conclude, Dr Costa highlights the importance of achieving MRD negativity at an early stage, and mentions the need to find less invasive ways of monitoring disease. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Research support: Amgen, Janssen, BMS, AbbVie, Ionis, Genentech
Honorarium: Amgen, Janssen, Sanofi, Karyopharm, BMS, Astra Zeneca, Adaptive Biotechnologies, Takeda, Pfizer
